Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study - PubMed (original) (raw)
Clinical Trial
. 2000 Sep 13;284(10):1247-55.
doi: 10.1001/jama.284.10.1247.
G Faich, J L Goldstein, L S Simon, T Pincus, A Whelton, R Makuch, G Eisen, N M Agrawal, W F Stenson, A M Burr, W W Zhao, J D Kent, J B Lefkowith, K M Verburg, G S Geis
Affiliations
- PMID: 10979111
- DOI: 10.1001/jama.284.10.1247
Clinical Trial
Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study
F E Silverstein et al. JAMA. 2000.
Abstract
Context: Conventional nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with a spectrum of toxic effects, notably gastrointestinal (GI) effects, because of inhibition of cyclooxygenase (COX)-1. Whether COX-2-specific inhibitors are associated with fewer clinical GI toxic effects is unknown.
Objective: To determine whether celecoxib, a COX-2-specific inhibitor, is associated with a lower incidence of significant upper GI toxic effects and other adverse effects compared with conventional NSAIDs.
Design: The Celecoxib Long-term Arthritis Safety Study (CLASS), a double-blind, randomized controlled trial conducted from September 1998 to March 2000.
Setting: Three hundred eighty-six clinical sites in the United States and Canada.
Participants: A total of 8059 patients (>/=18 years old) with osteoarthritis (OA) or rheumatoid arthritis (RA) were enrolled in the study, and 7968 received at least 1 dose of study drug. A total of 4573 patients (57%) received treatment for 6 months.
Interventions: Patients were randomly assigned to receive celecoxib, 400 mg twice per day (2 and 4 times the maximum RA and OA dosages, respectively; n = 3987); ibuprofen, 800 mg 3 times per day (n = 1985); or diclofenac, 75 mg twice per day (n = 1996). Aspirin use for cardiovascular prophylaxis (</=325 mg/d) was permitted.
Main outcome measures: Incidence of prospectively defined symptomatic upper GI ulcers and ulcer complications (bleeding, perforation, and obstruction) and other adverse effects during the 6-month treatment period.
Results: For all patients, the annualized incidence rates of upper GI ulcer complications alone and combined with symptomatic ulcers for celecoxib vs NSAIDs were 0.76% vs 1.45% (P =.09) and 2. 08% vs 3.54% (P =.02), respectively. For patients not taking aspirin, the annualized incidence rates of upper GI ulcer complications alone and combined with symptomatic ulcers for celecoxib vs NSAIDs were 0.44% vs 1.27% (P =.04) and 1.40% vs 2.91% (P =.02). For patients taking aspirin, the annualized incidence rates of upper GI ulcer complications alone and combined with symptomatic ulcers for celecoxib vs NSAIDs were 2.01% vs 2.12% (P =.92) and 4.70% vs 6.00% (P =.49). Fewer celecoxib-treated patients than NSAID-treated patients experienced chronic GI blood loss, GI intolerance, hepatotoxicity, or renal toxicity. No difference was noted in the incidence of cardiovascular events between celecoxib and NSAIDs, irrespective of aspirin use.
Conclusions: In this study, celecoxib, at dosages greater than those indicated clinically, was associated with a lower incidence of symptomatic ulcers and ulcer complications combined, as well as other clinically important toxic effects, compared with NSAIDs at standard dosages. The decrease in upper GI toxicity was strongest among patients not taking aspirin concomitantly. JAMA. 2000;284:1247-1255
Comment in
- COX-2-Selective NSAIDs: new and improved?
Lichtenstein DR, Wolfe MM. Lichtenstein DR, et al. JAMA. 2000 Sep 13;284(10):1297-9. doi: 10.1001/jama.284.10.1297. JAMA. 2000. PMID: 10980759 No abstract available. - Safety of celecoxib vs other nonsteroidal anti-inflammatory drugs.
Köhler L, Zeidler H, Merkesdal S, Kuipers JG. Köhler L, et al. JAMA. 2000 Dec 27;284(24):3123; author reply 3124. JAMA. 2000. PMID: 11135763 No abstract available. - Safety of celecoxib vs other nonsteroidal anti-inflammatory drugs.
Taylor B, van de Wal B. Taylor B, et al. JAMA. 2000 Dec 27;284(24):3123-4. JAMA. 2000. PMID: 11135764 No abstract available. - Reporting of 6-month vs 12-month data in a clinical trial of celecoxib.
Hrachovec JB, Mora M. Hrachovec JB, et al. JAMA. 2001 Nov 21;286(19):2398; author reply 2399-400. JAMA. 2001. PMID: 11712924 No abstract available. - Reporting of 6-month vs 12-month data in a clinical trial of celecoxib.
Wright JM, Perry TL, Bassett KL, Chambers GK. Wright JM, et al. JAMA. 2001 Nov 21;286(19):2398-400. JAMA. 2001. PMID: 11712925 No abstract available.
Similar articles
- Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial.
Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, Isakson PC, Verburg KM, Yu SS, Zhao WW, Geis GS. Simon LS, et al. JAMA. 1999 Nov 24;282(20):1921-8. doi: 10.1001/jama.282.20.1921. JAMA. 1999. PMID: 10580457 Clinical Trial. - Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.
Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ. Langman MJ, et al. JAMA. 1999 Nov 24;282(20):1929-33. doi: 10.1001/jama.282.20.1929. JAMA. 1999. PMID: 10580458 - The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
Hunt RH, Harper S, Watson DJ, Yu C, Quan H, Lee M, Evans JK, Oxenius B. Hunt RH, et al. Am J Gastroenterol. 2003 Aug;98(8):1725-33. doi: 10.1111/j.1572-0241.2003.07598.x. Am J Gastroenterol. 2003. PMID: 12907325 Clinical Trial. - Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
Chen YF, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G, Taylor RS. Chen YF, et al. Health Technol Assess. 2008 Apr;12(11):1-278, iii. doi: 10.3310/hta12110. Health Technol Assess. 2008. PMID: 18405470 Review. - What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
Hochberg MC. Hochberg MC. Clin Exp Rheumatol. 2001 Nov-Dec;19(6 Suppl 25):S15-22. Clin Exp Rheumatol. 2001. PMID: 11695246 Review.
Cited by
- Exploring the Causal Relationship between Ibuprofen Use and Osteoarthritis Risk: A Mendelian Randomization Study.
Jian Y, Lyu Y, Hashemolhosseini S. Jian Y, et al. Biology (Basel). 2024 Sep 23;13(9):748. doi: 10.3390/biology13090748. Biology (Basel). 2024. PMID: 39336175 Free PMC article. - NSAIDs between past and present; a long journey towards an ideal COX-2 inhibitor lead.
Khalil NA, Ahmed EM, Tharwat T, Mahmoud Z. Khalil NA, et al. RSC Adv. 2024 Sep 25;14(42):30647-30661. doi: 10.1039/d4ra04686b. eCollection 2024 Sep 24. RSC Adv. 2024. PMID: 39324041 Free PMC article. Review. - Susceptibility of Staphylococcus aureus to Anti-Inflammatory Drugs with a Focus on the Combinatory Effect of Celecoxib with Oxacillin In Vitro.
Okpala OE, Rondevaldova J, Osei-Owusu H, Kudera T, Kokoskova T, Kokoska L. Okpala OE, et al. Molecules. 2024 Aug 2;29(15):3665. doi: 10.3390/molecules29153665. Molecules. 2024. PMID: 39125072 Free PMC article. - Chronic Low Back Pain: History, Symptoms, Pain Mechanisms, and Treatment.
Farley T, Stokke J, Goyal K, DeMicco R. Farley T, et al. Life (Basel). 2024 Jun 27;14(7):812. doi: 10.3390/life14070812. Life (Basel). 2024. PMID: 39063567 Free PMC article. Review. - Pyrazoles as Anti-inflammatory and Analgesic Agents: In-vivo and In-silico Studies.
Chahal G, Monga J, Rani I, Saini S, Devgun M, Husain A, Lal Khokra S. Chahal G, et al. Antiinflamm Antiallergy Agents Med Chem. 2024;23(1):39-51. doi: 10.2174/0118715230275741231207115011. Antiinflamm Antiallergy Agents Med Chem. 2024. PMID: 38828869
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials